Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH

Journal of Thrombosis and Haemostasis

Volumn 14, Issue 8, 2016, Pages 1673-1676

  Cohen, H ^a,b   Arachchillage, D R ^a   Middeldorp, S ^c   Beyer Westendorf, J ^d   Abdul Kadir, R ^e,f  

^a UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UNIVERSITY OF AMSTERDAM   (Netherlands)

^d UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f ROYAL FREE HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; APIXABAN; DABIGATRAN ETEXILATE; EDOXABAN; LOW MOLECULAR WEIGHT HEPARIN; RIVAROXABAN;

ACUTE CORONARY SYNDROME; ARTICLE; ATRIAL FIBRILLATION; BREAST FEEDING; CEREBROVASCULAR ACCIDENT; CONTRACEPTION; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG MILK LEVEL; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EMBOLISM; FEMALE; FETOTOXICITY; FETUS MONITORING; GESTATIONAL AGE; HUMAN; MOLECULAR WEIGHT; NONHUMAN; PLACENTAL TRANSFER; PREGNANCY OUTCOME; PREGNANCY TERMINATION; PREGNANT WOMAN; PRIORITY JOURNAL; REPRODUCTIVE TOXICITY; SINGLE DRUG DOSE; TERATOGENICITY; UNPLANNED PREGNANCY; VENOUS THROMBOEMBOLISM;

EID: 84983288382     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/jth.13366     Document Type: Article

References (26)

1. Pradaxa 150 mg hard capsules. Summary of Product Characteristics. www.emc.medicines.org.uk/emc/medicine/24839. Accessed 30 September 2015.
2. Eliquis 5 mg film-coated tablets film-coated tablets. Summary of Product Characteristics. www.emc.medicines.org.uk/EMC/medicine/27220. Accessed 1 October 2015.
3. Lixiana 60 mg film-coated tablets. Summary of Product Characteristics. www.emc.medicines.org.uk/emc/medicine/30506. Accessed 1 July 2015.
4. Xarelto 15 and 20 mg film-coated tablets. Summary of Product Characteristics. www.emc.medicines.org.uk/emc/medicine/25591. Accessed 14 July 2015.
5. Schulman S, Kearon C, Kakkar AK, Mismetti P, Schellong S, Eriksson H, Baanstra D, Schnee J, Goldhaber SZ; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342–52.
6. Schulman S, Kakkar AK, Goldhaber SZ, Schellong S, Eriksson H, Mismetti P, Christiansen AV, Friedman J, Le Maulf F, Peter N, Kearon C; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129: 764–72.
7. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799–808.
8. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Porcari A, Raskob GE, Weitz JI; PLIFY-EXT Investigators. Apixaban for extended treatment of venous thromboembolism. N Engl J Med 2013; 368: 699–708.
9. Hokusai-VTE Investigators, Büller HR, Décousus H, Grosso MA, Mercuri M, Middeldorp S, Prins MH, Raskob GE, Schellong SM, Schwocho L, Segers A, Shi M, Verhamme P, Wells P. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406–15.
10. EINSTEIN Investigators, Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells P, Agnelli G, Bounameaux H, Cohen A, Davidson BL, Piovella F, Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499–510.
11. The EINSTEIN–PE Investigators, Büller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells P, Agnelli G, Cohen A, Berkowitz SD, Bounameaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287–97.
12. Arachchillage DJ, Cohen H. Use of new oral anticoagulants in antiphospholipid syndrome. Curr Rheumatol Rep 2013; 15: 331.
13. Königsbrügge O, Langer M, Hayde M, Ay C, Pabinger I. Oral anticoagulation with rivaroxaban during pregnancy: a case report. Thromb Haemost 2014; 112: 1323–4.
14. Douketis JD, Weitz JI. Guidance, guidelines, and communications. J Thromb Haemost 2014; 12: 1744–5.
15. Bapat P, Kedar R, Lubetsky A, Matlow JN, Aleksa K, Berger H, Koren G. Transfer of dabigatran and dabigatran etexilate mesylate across the dually perfused human placenta. Obstet Gynecol 2014; 123: 1256–61.
16. Wang L, He K, Maxwell B, Grossman SJ, Tremaine LM, Humphreys WG, Zhang D. Tissue distribution and elimination of [14C]apixaban in rats. Drug Metab Dispos 2011; 39: 256–64.
17. Bapat P, Pinto LS, Lubetsky A, Berger H, Koren G. Rivaroxaban transfer across the dually perfused isolated human placental cotyledon. Am J Obstet Gynecol 2015; 213: 710. e1–6.
18. Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet 2004; 43: 487–514.
19. Jonker JW, Smit JW, Brinkhuis RF, Maliepaard M, Beijnen JH, Schellens JH, Schinkel AH. Role of breast cancer resistance protein in the bioavailability and fetal penetration of topotecan. J Natl Cancer Inst 2000; 92: 1651–6.
20. Lankas GR, Wise LD, Cartwright ME, Pippert T, Umbenhauer DR. Placental P-glycoprotein deficiency enhances susceptibility to chemically induced birth defects in mice. Reprod Toxicol 1998; 12: 457–63.
21. Ceckova-Novotna M, Pavek P, Staud F. P-glycoprotein in the placenta: expression, localization, regulation and function. Reprod Toxicol 2006; 22: 400–10.
22. Pacifici GM, Nottoli R. Placental transfer of drugs administered to the mother. Clin Pharmacokinet 1995; 28: 235–69.
23. Eisert WG, Hauel N, Stangier J, Wienen W, Clemens A, van Ryn J. Dabigatran: an oral novel potent reversible nonpeptide inhibitor of thrombin. Arterioscler Thromb Vasc Biol 2010; 30: 1885–9.
24. Moore KL, Persaud TVN, Torchia MG. Human birth defects. In: Moore KL, Persaud TVN, Torchia MG, eds. The Developing Human: Clinically Oriented Embryology, 9th edn. Philadelphia, PA: Saunders/Elsevier, 2013: 471–501.
25. Hoeltzenbein M, Beck E, Meixner K, Schaefer C, Kreutz R. Pregnancy outcome after exposure to the novel oral anticoagulant rivaroxaban in women at suspected risk for thromboembolic events: a case series from the German Embryotox Pharmacovigilance Centre. Clin Res Cardiol 2016; 105: 117–26.
26. Rudd KM, Winans AR, Panneerselvam N. Possible rivaroxaban failure during the postpartum period. Pharmacotherapy 2015; 35: e164–8.